Dossier assessment
Dapagliflozin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Report documents
-
Extract of dossier assessment
Dapagliflozin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
-
Dossier assessment
Dapagliflozin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Press releases
Added benefit of the fixed combination of dapagliflozin and metformin is not proven
Drug manufacturer's dossier did not contain suitable data for any therapeutic indication
Additional information
Federal Joint Committee (G-BA)
2014-08-07 A G-BA decision was published.
Project details
- Project no.
- A14-07
- Commission
- Commission awarded on 05.02.2014 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed